Study of Exchange of Travoprost Intraocular Implant
Trial details
- Registry ID
- NCT04615403
- Phase
- Phase 2
The FDA approved Travoprost on 16 Mar 2001.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Exchange of Travoprost Intraocular ImplantNCT04615403 | Glaukos Corporation | Phase 2 | Completed | 2022-02-28Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2001-03-16Day | Travoprost | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA021257", "applicant_as_listed_by_fda": "ALCON PHARMS LTD", "brand_names": ["TRAVATAN"], "active_ingredients": ["TRAVOPROST"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20010316", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |